NCT06819423

Brief Summary

This study aims to evaluate the impact of AI-based fundus imaging on blood glucose control and fundus examination completion rates in diabetic patients by comparing outcomes between those who undergo AI fundus imaging and those who do not. The study is designed as a parallel randomized controlled trial (RCT). Using a random number table, 200 diabetic patients visiting the Department of Endocrinology at Sichuan Provincial People's Hospital between December 2024 and December 2025 will be equally divided into two groups: an intervention group and a control group. Each group will consist of 100 patients, assigned unique random numbers. The intervention group will undergo AI-based fundus imaging once, with the imaging process taking approximately 5 minutes. The control group will receive standard eye health education without AI fundus imaging. The primary outcomes, including blood glucose control, systemic indicators, and fundus examination completion rates, will be assessed and compared between the two groups at 3-month and 6-month follow-ups. This study seeks to determine the value of AI-based fundus imaging in improving diabetes management and complication prevention in diabetic patients.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P50-P75 for not_applicable diabetes

Timeline
Completed

Started Dec 2024

Shorter than P25 for not_applicable diabetes

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 26, 2024

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

February 5, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 11, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 26, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 26, 2025

Completed
Last Updated

February 11, 2025

Status Verified

February 1, 2025

Enrollment Period

1 year

First QC Date

February 5, 2025

Last Update Submit

February 10, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • fasting blood glucose level

    Blood Glucose Control Status in Two Groups of Patients

    From enrollment to reexamination at 3 months and 6 months

  • Blood Glucose Control Status in Two Groups of Patients after 3 Months and 6 Months

    glycated hemoglobin (HbA1c) level

    From enrollment to reexamination at 3 months and 6 months

Study Arms (2)

Patients with diabetes who received health education and AI fundus photography in our hospital

EXPERIMENTAL
Device: AI fundus photography

Patients with diabetes who received health education in our hospital

NO INTERVENTION

Interventions

In the dark room, Canon CR-2AF automatic mydria-free fundus camera was used to collect images of both eyes of the patients, and one fundus photo was taken with macula as the center of each eye

Patients with diabetes who received health education and AI fundus photography in our hospital

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years.
  • Diagnosis of Type 2 Diabetes Mellitus.
  • Patients with a glycated hemoglobin (HbA1c) level \> 7%.
  • Ability to comply with all required examinations and provide signed informed consent.

You may not qualify if:

  • No previous diabetic fundus examination.
  • No known diabetic retinopathy.
  • Absence of other ocular diseases that could lead to retinopathy.
  • Subjects from whom clear fundus photographs could not be obtained.
  • Patients with comorbid malignant tumors or severe cardiovascular diseases.
  • Patients anticipated to have difficulties with follow-up or those residing in other provinces.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sichuan Academy of Medical Sciences - Sichuan Provincial People's Hospital

Chengdu, Sichuan, 610014, China

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SCREENING
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 5, 2025

First Posted

February 11, 2025

Study Start

December 26, 2024

Primary Completion

December 26, 2025

Study Completion

December 26, 2025

Last Updated

February 11, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will share

2030, via https://pan.baidu.com

Shared Documents
CSR
Time Frame
2025 and forever
Access Criteria
via https://pan.baidu.com
More information

Locations